Le coin des francophones Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Le coin des francophones

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: kamtrader who wrote (19999)	6/19/2000 3:36:00 PM
From: recafe	Read Replies (1) of 77509

oui kam voila 2 bouts de texte qui explique pouquoi je prefere incy (Genomic Explosion Celera deserves credit for being aggressive, and it may well be the industry's leader for some time. But I prefer other genomic companies, such as Incyte (Nasdaq:INCY - news), Human Genome Sciences (Nasdaq:HGSI - news), Millennium (Nasdaq:MLNM - news) and Myriad Genetics (Nasdaq:MYGN - news) for the long haul. They've made more progress, are more established and look like they will deliver on their promises to the market.)(Insight on Incyte For mining the human genome, I've always been an advocate of Incyte. This company was the original genomic company, which came up with the business model of using computers and building databases for sale. Then Celera came onstage and knocked Incyte out of the spotlight. Celera can offer genetic databases that aren't limited to human genes, and that includes other species for comparison, such as the mouse and fruit fly. In my opinion, however, Incyte is just as competitive and as solid a company. mais elmg messieur ca c'est du stock ca.biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next